Evidence map›Paper›PMID 39682212›Full record

ArticleCancers2024

Postoperative Radiotherapy for pT1- and pT2-Classified Squamous Cell Carcinoma of the External Auditory Canal.

Cindy H Nabuurs, Wietske Kievit, Charles René Reinier Leemans, Conrad F G M Smit, Michiel W M van den Brekel, Robert J Pauw, Bernard F A M van der Laan, Jeroen C Jansen, Martin Lacko, Weibel W Braunius and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Cindy H NabuursDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0001-8894-4329
Wietske KievitDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Charles René Reinier LeemansDepartment of Otolaryngology-Head and Neck Surgery, Amsterdam University Medical Centers, VU University, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0001-7887-083X
Conrad F G M SmitDepartment of Otolaryngology-Head and Neck Surgery, Amsterdam University Medical Centers, VU University, 1081 HV Amsterdam, The Netherlands.
Michiel W M van den BrekelDepartment of Head and Neck Surgery and Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0002-6338-6743
Robert J PauwDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
Bernard F A M van der LaanDepartment of Otorhinolaryngology and Head and Neck Surgery, University Medical Center of Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-5016-2871
Jeroen C JansenDepartment of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-3955-0152
Martin LackoDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.ORCID 0000-0003-2868-4822
Weibel W BrauniusDepartment of Head and Neck Surgical Oncology, University Medical Center, Utrecht Cancer Center, 3584 CG Utrecht, The Netherlands.
Chunfu DaiDepartment of Otology & Skull Base Surgery, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai 200437, China.
Xunbei ShiDepartment of Otology & Skull Base Surgery, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai 200437, China.
Giovanni DanesiDepartment of Otorhinolaryngology and Skull Base Microsurgery-Neurosciences, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, 24127 Bergamo, Italy.
Jan BoučekDepartment of Otorhinolaryngology, Head and Neck Surgery, The First Faculty of Medicine, Charles University in Prague, University Hospital Motol, 150 06 Prague, Czech Republic.
Daniele BorsettoDepartment of Otorhinolaryngology, Head and Neck Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Shravan GowrishankarDepartment of Otorhinolaryngology, Head and Neck Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Romain KaniaDepartment of Head and Neck Surgery, Lariboisière University Hospital, 75010 Paris, France.
Clément JourdaineDepartment of Head and Neck Surgery, Lariboisière University Hospital, 75010 Paris, France.
Thijs T G JansenDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Jolanda DerksDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Tim DijkemaDepartment of Radiation Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Robert P TakesDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Henricus P M KunstDepartment of Otorhinolaryngology and Head and Neck Surgery-Academic Alliance Skull Base Pathology Radboudumc & MUMC+, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is no consensus regarding the indication for postoperative radiotherapy (PORT) for T1- and T2-classified squamous cell carcinoma (SCC) of the external auditory canal (EAC) even with negative surgical margins. This study aimed to evaluate whether PORT provides additional benefits for these cases.

methodsWe collected retrospective data from fourteen international hospitals, including resected pT1- and pT2-classified EAC SCC with negative surgical margins.

resultsA total of 112 early-stage radically resected EAC SCC were included, with 48 patients receiving PORT. The 5-year DFS of T1- and T2-classified EAC SCC treated with PORT was not statistically significantly different (92.9% and 76.9%, respectively) compared to the group treated without PORT (100% and 90.9%, respectively;

conclusionsOur study suggests that PORT for early-stage radically resected EAC SCC should only be considered in selected cases with perineural, infiltrative growth or angioinvasive growth, and with a close margin. This approach helps mitigate the negative impact on quality of life and the risk of side effects associated with radiotherapy.

Indexed as

disease-free survivalradiotherapysquamous cell carcinomatemporal bonetreatment

Identifiers

PMID39682212
PMCPMC11640678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.